tumor protein p63Genealiases: AIS · B(p51A) · B(p51B) · EEC3 · KET · LMS
Q-omics provides the consensus-scored TP63 profile across patient tissues and cancer cell-line models. TP63 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TP63 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TP63 protein abundance shows 22,015 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where TP63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP63 survival associations across molecular data types. TP63 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP63 RNA expression–survival associations across cancer types. High TP63 expression shows unfavorable associations in KIRP and PAAD, but favorable associations in BRCA, LUSC, UCS and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TP63 RNA expression.
This table summarizes TP63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TP63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP63 shows lower tumor expression in KIRC, BRCA and KIRP and higher tumor expression in HNSC, LUSC and UCEC. The HNSC box plot shows higher TP63 RNA expression in tumor versus normal tissue (log2 FC = +2.057, t-test p < 0.001).
This table shows molecular features associated with TP63 in patient tissues and cancer cell lines. In patient samples, TP63 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TP63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
